Clinical trial
Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the…
NCT00281593 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00281593 |
|---|---|
| Title | Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension |
| Official title | A Randomized, Double-blind, Double-dummy, Placebo-controlled, 3x4 Factorial Design Trial to Evaluate Telmisartan 20 and 80 mg Tablets in Combination With Ramipril 1.25, 10, and 20 mg Capsules After Eight Weeks of Treatment in Patients With Stage I or II Hypertension, With an ABPM Sub-study |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Telmisartan, Ramipril |
| Enrollment | 1,354 |
| Start date | Apr 1, 2006 |
| Primary completion | Apr 1, 2007 |
| First posted | Jan 25, 2006 |
| Last update posted | Dec 28, 2017 |
| Countries | Argentina, Canada, Chile, Mexico, Peru, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: